Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Single-Center, Double-Blind, Randomized, Placebo Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and P… Recruiting

2025-523885-25-00 Healthy Volunteers 2026-01-21
A study to find a suitable dose of ASP5834 in adults with solid tumors Recruiting

2025-522082-29-00 Locally advanced (unresectable) or metastatic solid tum 2026-01-16
A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy Recruiting

2025-523469-79-00 Spinal and Bulbar Muscular Atrophy 2026-01-16
A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healt… Recruiting

2025-523115-11-00 Phase I study in healthy participants. Intended indicat 2026-01-14
Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy. Recruiting

2023-507106-13-00 Locally advanced rectal cancer 2026-01-12
A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of hea… Recruiting

2025-523301-15-00 Vasodilatory shock 2025-12-17
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced S… Recruiting

2025-521407-52-00 Advanced Solid Tumors 2025-12-16
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting

2024-513619-28-00 Clear Cell Renal Cell Carcinoma 2025-12-11
A Study to Investigate the Safety, Tolerability, and Exposure of Single Doses of the study medicine STK-002, in Patients with Autosomal Domi… Recruiting

2023-506290-35-00 Autosomal Dominant Optic Atrophy 2025-12-08
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Recruiting

2024-514763-25-01 spinocerebellar ataxia type 2 2025-12-04
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease. Recruiting

2024-518528-54-00 Active systemic lupus erythematosus (SLE), systemic scl 2025-12-02
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting

2024-519727-18-00 Metastatic Solid Tumor Advanced Solid Tumor Non-small C 2025-11-25
First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD) Recruiting

2025-521431-37-00 Parkinson's disease 2025-11-20
A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with d… Recruiting

2025-522002-20-00 PLN R14del Dilated Cardiomyopathy 2025-11-20
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS Recruiting

2025-523872-22-00 Parkinsons's Disease and amyotrophic lateral sclerosis 2025-11-18
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033 Recruiting

2024-520409-38-00 Eosinophilic esophagitis (EoE) 2025-11-14
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes Recruiting

2024-519382-22-00 Healthy Participants and Participants with type 2 diabe 2025-11-10
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors Recruiting

2025-521535-36-00 Locally advanced, metastatic NSCLC, CRC, or HNSCC that 2025-11-03
A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS Recruiting

2025-521876-77-00 Cholestatic liver disease 2025-11-03
A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced c… Recruiting

2024-511501-37-00 Advanced solid tumours 2025-10-31
A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and ph… Recruiting

2025-521556-35-00 Narcolepsy 2025-10-28
Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease. Recruiting

2025-523254-14-00 Parkinson's disease 2025-10-27
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors. Recruiting

2025-521916-20-00 Cancer 2025-10-24
A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch R… Recruiting

2025-522774-36-00 Advanced solid tumors 2025-10-24